Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds

• US 5,302,617 A
• Filed: 08/20/1992
• Issued: 04/12/1994
• Est. Priority Date: 04/27/1990
• Status: Expired due to Term

• Current Assignee: Sucampo AG (Mallinckrodt plc)
• Original Assignee: Kabushikikaisha UENO Seiyaku OYO Kenkyujo
• Inventors: Ueno, Ryuji
• Primary Examiner(s): Waddell, Frederick E.
• Assistant Examiner(s): Henley, III, Raymond J.
• Application Number:
  US07/932,690
• Time in Patent Office: 600 Days
• Field of Search: 514/573
• US Class Current: 514/573
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins

Abstract

A method for treatment of an allergic disease which comprises administering, to a subject in need of such treatment, a 15-dehydroxy-16-oxoprostaglandin compound in an amount effective in treatment of the allergic disease

Claims

1. A method for treatment of an allergic disease which comprises administering, to a subject in need of such treatment, a 15-dehydroxy-16-oxoprostaglandin compound in an amount effective in treatment of the allergic disease.

2. A method according to claim 1, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 17-mono- or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

3. A method according to claim 1, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-halo-15-dehydroxy-16- oxoprostaglandin compound.

4. A method according to claim 1, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-fluoro-15-dehydroxy-16-oxoprostaglandin compound.

25. A method according to claim 1, wherein said 15-dehydroxy-16-oxoprostaglandin compound is represented by the following formula:

##STR5## wherein X and Y ar hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl or oxo, with the proviso that a least one of X and Y is a group other than hydrogen, and 5-membered ring may have at least one double bond, Z is hydrogen or halo, A is--CH₂ OH, --COCH₂ OH, --COOH or its functional derivative, B is --CH₂ --CH₂ --CH₂ --. --CH═

CH--CH₂ --, --CH₂ --CH═

CH--, --C.tbd.C--CH₂ --or --CH₂ --C.tbd.C--, R₁ is a bivalent saturated or unsaturated, straight or blanched chain hydrocarbyl group having 1 to 14 carbon atoms which is unsubstituted or substituted with halo, oxo, or aryl, R₂ is a saturated or unsaturated, straight or branched chain hydrocarbyl group having 1 to 14 carbon atoms which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, aryl or aryloxy.

26. A method according to claim 25, wherein X is hydroxy and Y is oxo.

5. A method for treatment of an inflammatory disease which comprises administering, to a subject in need of such treatment, a 15-dehydroxy-16-oxoprostaglandin compound in an amount effective in treatment of the inflammatory disease.

6. A method according to claim 5, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 17-mono- or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

7. A method according to claim 5, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

8. A method according to claim 5, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-fluoro-15-dehydroxy-16-oxoprostaglandin compound.

9. A method for treatment of a disease treatable by a antihistaminic agent which comprises administering, to a subject in need of such treatment, an antihistaminically effective amount of a 15-dehydroxy-16-oxoprostaglandin compound.

10. A method according to claim 9, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 17-mono- or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

11. A method according to claim 9, wherein said 15- dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

12. A method according to claim 9, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-fluoro-15-dehydroxy-16-oxoprostaglandin compound.

13. A method for treatment of a disease treatable by a leukotriene antagonist which comprises administering, to a subject in need of such treatment, a 15-dehydroxy-16-oxoprostaglandin compound in an amount effective in antagonism against a leukotriene.

14. A method according to claim 13, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 17-mono- or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

15. A method according to claim 13, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

16. A method according to claim 13, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-fluoro-15-dehydroxy-16-oxoprostaglandin compound.

17. A method for treatment of a disease treatable by a platelet activating factor antagonist which comprises administering, to a subject in need of such treatment, a 15-dehydroxy-16-oxoprostaglandin compound in an amount effective in antagonist against the platelet activating factor.

18. A method according to claim 17, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 17-mono- or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

19. A method according to claim 17, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

20. A method according to claim 17, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-fluoro-15-dehydroxy-16-oxoprostaglandin compound.

21. A method for treatment of a disease treatable by bronchodilatation which comprises administering, to a subject in need of such treatment, a 15-dehydroxy-16-oxoprostaglandin compound in an amount effective in causing bronchodilatation.

22. A method according to claim 21, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 17-mono- or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

23. A method according to claim 21, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-halo-15-dehydroxy-16-oxoprostaglandin compound.

24. A method according to claim 21, wherein said 15-dehydroxy-16-oxoprostaglandin compound is a 13,14-dihydro-17-mono or di-fluoro-15-dehydroxy-16-oxoprostaglandin compound.